ArticleDrug design, development and therapy2026
Towards Personalized Tacrolimus Dosing Using an Algorithm-Driven Prediction Pipeline for Kidney Transplant.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tacrolimus (TAC) dosing presents a persistent challenge in postoperative care owing to its narrow therapeutic window and high inter‑patient variability, which often leads to suboptimal exposure with increasing risks of nephrotoxicity or graft rejection. Algorithm‑based personalized dosing strategies offer a promising approach to support clinical decision and improve long‑term outcomes. Methods: Unlike approaches relying on a wide range of variables and local clinical scopes, this study proposed a novel and versatile algorithm-driven strategy to predict TAC doses. A hybrid optimization method was first employed to identify a minimal set of key clinical factors. These factors were then used to construct a cascaded deep forest model capable of predicting both follow‑up and initial TAC doses in adult kidney transplant recipients. Results: When validated on 615 patients using leave-one-subject-out cross-validation, it achieved predictions within ±20% of actual values, with an accuracy of 89.8% for follow-up doses and 83.2% for initial doses. Independent external validation confirmed its robustness. A Shapley additive explanation analysis revealed significant correlations between input features and predictive doses. To support real-time clinical use, an open‑access web platform was provided (http://www.jcu-qiulab.com/tacp/). Conclusion: This approach offers a practical, effective, and algorithm-driven pipeline for automated drug dose analysis and prediction in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.